Drug News
-
Narcolepsy Drugs Market Soars to $5.95 Billion by 2030: Sodium Oxybate Takes Center Stage in Global Forecast
The Narcolepsy Drugs Market is on an upward trajectory, projected to reach a substantial value of US$5.95 billion by 2030,…
Read More » -
Stuart Therapeutics Unveils Breakthrough Phase 3 Clinical Trial for Vezocolmitide, a Potential Game-Changer in Dry Eye Disease Treatment
Stuart Therapeutics, Inc. (“Stuart”), a cutting-edge biopharmaceutical company specializing in extracellular matrix-targeting peptide therapeutics for ophthalmic diseases, has marked a…
Read More » -
Acelyrin, Inc. Faces Wrath of Investors in Landmark Securities Class Action
Kessler Topaz Meltzer & Check, LLP has announced the initiation of a securities class action lawsuit against Acelyrin, Inc. (NASDAQ:…
Read More » -
Drugmakers to Increase Prices on Over 500 Drugs in January
According to an exclusive report by Reuters, several major pharmaceutical companies, including Pfizer, Sanofi, and Takeda Pharmaceutical, are set to…
Read More » -
MiMedx Group Receives FDA Warning Letter for Axiofill; Shares Decline 7%
MiMedx Group Inc, a biopharmaceutical company, reported on Friday that it has received a warning letter from the U.S. Food…
Read More » -
Corcept Loses Patent Dispute Against Teva, Shares Tumble
A U.S. judge ruled in favor of Teva Pharmaceutical Industries in a patent infringement lawsuit filed by Corcept Therapeutics, leading…
Read More » -
McKinsey Agrees to Pay $78 Million in Final Settlement Over Alleged Role in U.S. Opioid Epidemic
Consulting firm McKinsey & Co has reached a final settlement of $78 million to resolve claims made by U.S. health…
Read More » -
FDA Updates Guidance on Topical Ophthalmic Drug Quality
In a significant development for the pharmaceutical industry, the U.S. Food and Drug Administration (FDA) has made an announcement regarding…
Read More » -
Jemincare’s Wholly Owned Subsidiary Secures 6 Clinical Trial Approvals for Innovative Drugs
Jemincare, a prominent Chinese pharmaceutical company, has announced significant progress in its drug development endeavors. Its wholly-owned subsidiary, Shanghai Jemincare…
Read More » -
Innovent Biologics and Sanegene Bio to Collaborate on Innovative siRNA Drug for Hypertension Treatment
Innovent Biologics, a prominent biopharmaceutical company, and Sanegene Bio USA have announced a strategic collaboration to co-develop SGB-3908, an siRNA…
Read More »